{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "c10d5a916abd21c6befb6f57fc80f050",
    "title": "Weekend Healthcare Pulse: Global pharma shopping spree - recovery in M&A and license deals",
    "source_uri": "2025-08-29/Weekend Healthcare Pulse Global pharma shopping spree recovery in MA and license deals Weekend Healthcare Pulse Global p_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T23:52:49.219383",
      "extracted_at": "2025-10-26T23:52:49.219390"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 17,
        "successful_pages": 17,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 1,
          "removed_paragraphs": 4,
          "reduction_ratio": 0.04237827257156834
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "8064b49f7329753b",
      "text": "Readers are probably aware that the pharma industry faces major patent cliffs in the next decade, with estimates putting the total drug revenues exposed at hundreds of billions (Exhibit 1, Exhibit 2). This includes top- selling drugs like Keytruda (\\$30 Bn), Opdivo (\\$ Ozempic (\\$17 Bn), Eyelea (\\$5 Bn), Entresto (\\$4 Bn), to name a few. A famous example of sales loss post- LOE is Humira. Once the global best- selling drug with over \\$20 Bn sales in 2021- 2022, lost c. 25% of its business in 2023, the first year post LOE, and further shrank to less than a half (\\$9 Bn) in 2024.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ea0b3bd62f689199",
      "text": "With the looming waves of LOE, Big Pharma has to stock up their pipelines faster than before, and in- house R&D alone does not bridge the gap. Companies shore up external assets, and we see a recovery of M&A activities in 2025 from the trough last year, and more significantly, a boom of licensing deals. Where and what are they shopping, what's changed, and what would be the trend going forward?",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7865d9e181c9e4ae",
      "text": "EXHIBIT 1: Bernstein EU pharma coverage revenue estimates with upcoming loss of exclusivity (LOE)",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "d44db180568b3281",
      "text": "(1) AZN = AstraZeneca, BAYN = Bayer; GSK = GSK, IPN = Ipsen, MRK = Merck KGaA; NOVN = Novartis, NOVO = Novo Nordisk, ROG = Roche, SAN = Sanofi; UCB = UCB SA (2) Sales depicted are global sales even though geographic patent expires are spread across several years Source: Bernstein analysis & estimates; company reports",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "71525a40f480a2eb",
      "text": "EXHIBIT 2: Bernstein US Coverage LOE exposure",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4dbc52c5c4e10aac",
      "text": "MRK = Merck & Co, BMY = Bristol Myers- Squibb, PFE = Pfizer, AMGN = Amgen, ABBV = AbbVie, GILD = Gilead, LLY = Eli Lilly Source: EvaluatePharma, Bernstein analysis",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "2268aedc1e348992",
      "text": "Heightened M&A activities in 2025 YTD. We observe materially stronger M&A transaction activities in 2025 YTD at US \\(58Bn, on par with 2024 total. Looking back, 2019 was a high year driven by large deals, including AbbVie's acquisition of Allergan at US\\) 63Bn and BMS's purchase of Celgene at US \\(74Bn, with an average deal premium of 126%. The following years were quite stable in deal numbers but saw a significant decrease in total deal value, reflecting a more cautious shift towards smaller- sized deals amid valuation re- rating. 2024 was an all- time low, affected by valuation and the macroeconomic environment. So far this year, we have seen improvement in average deal value as an upturn from 2024, but still lagging behind previous years. In general, large pharma M&A activities carry an average deal premium of \\~60%- 90%, representing a favorable position in the capital market (Exhibit 3).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3040d951dff12ee7",
      "text": "EXHIBIT 3: Recovery of M&A activities in 2025 YTD",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "23abfb6f371fb641",
      "text": "Bloomberg subsector:Large pharma Source: Bloomberg, Bernstein analysis",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "324696e69448eb4b",
      "text": "2025 YTD. Compared to double- digit total deal value of M&A activities, we see a higher value of global licensing transactions at US \\(163 Bn YTD with upfront payment at US\\) 13Bn, already catching up 2022- 24 levels in the first eight months of 2025. The",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "673288e2282fd08b",
      "text": "average deal value is also significant compared to previous years, with a lower deal count but likewise total deal value. It seems that while M&A activities are still sluggish, global biotech and pharma players have been more active in licensing activities (Exhibit 4, Exhibit 5).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "679edf0198daf611",
      "text": "EXHIBIT 4: More pronounced rebound in global licensing activity than M&A in 2025 YTD",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "bde1481955493666",
      "text": "Source:Pharmcubebernstein analysis",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "4fe8113017e9e05d",
      "text": "EXHIBIT 5: Total deal value sees a \\(62.41\\%\\) YoY increase in Jan - Jul 2025",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "faef2c586298f3a6",
      "text": "TDV of license deals (≥US \\(500 Mn) Source: Bloomberg, pharmcubebernstein analysis",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "77f0b0bee204eb3e",
      "text": "Global M&A: Shopping destinations haven't changed much On the acquirer side, U.S. remains the top acquirer for M&A activities in 2022 and 2025 YTD, demonstrating sustained interest from U.S. biotech and pharma companies. There has been significant growth in European acquisitions in 2025 YTD compared to 2022 (US \\(25.8 Bn vs.12.8 Bn). This increase has been driven primarily by Sanofi's major transactions (totaling US\\)11.6 Bn), including the acquisitions of Vicerio, Blueprint Medicines, and Vigil Neuroscience. Additionally, Novartis (US \\(4.8Bn vs. none) and Merck KGaA (US\\)3.9 Bn vs. 0.8 Bn) have shown notable increases in activity, while GSK (US\\)3.2 Bn vs. 5.2 Bn) has seen a slight decline. China M&A activities stayed still, with the 2025 YTD M&A deal value mainly contributed by Sinopharm's acquisition of La Nova (US\\)0.95 Bn) (Exhibit 6, Exhibit 7).",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "d5e333843b1e337d",
      "text": "On the deal target side, U.S. is still the most favorable target country for M&A activities (US\\$49.7 Bn vs. 52.7 Bn, 2025 YTD vs. 2022). Most buyers of U.S. targets are domestic, accounting for 37 out of 53 deals (70%, percentage unchanged from 2022). There was a decline of interest in Europe (US\\$14.5 Bn vs. 32.5 Bn, 2025 YTD vs. 2022), mainly contributed by a decrease in Amgen's investment (US\\$27.8 Bn vs. none, 2025 YTD vs. 2022), and offset by Merck & Co.'s acquisition of Verona Pharma at TDV of US\\$10 Bn earlier this year (Exhibit 8, Exhibit 9).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "ec900e4c8115a75e",
      "text": "EXHIBIT 6: U.S. remains the top acquirer in 2022 and 25",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "c7615d2ed3022ccc",
      "text": "EXHIBIT 7: European acquirers express growing interest",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "7e1f0c8759ff5fe1",
      "text": "TDV = Total Deal Value Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "44b115d47b820334",
      "text": "TDV = Total Deal Value Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "d8503d8737971453",
      "text": "EXHIBIT 8: US targets are most favorable for M&A",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1d32e1521dddd49c",
      "text": "EXHIBIT 8: US targets are most favorable for M&A",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "bed11bc371ae557c",
      "text": "EXHIBIT 9: Decline of interest in European M&A targets",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1a088d51e660012d",
      "text": "TDV = Total Deal Value Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "1ce90cba9b7fb1f3",
      "text": "TDV = Total Deal Value; South Korea 2025 YTD data not available Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5e414f9593299e48",
      "text": "U.S. and China continue to dominate the licensing market, with Korea showing increased activity in both in-and-out-license. The ranking of licensees largely stayed the same in 2022 and 2025 YTD. U.S. purchased 149 licenses so far in 2025 and China comes the second at 89. Notably, there has been an increase in Korean in-licensing activities, rising from 26 in 2022 to 39 in 2025 YTD (Exhibit 10- Exhibit 11).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "57ea6491935108fd",
      "text": "China is narrowing the out- license gap with the U.S. Back in 2022, China out- license deals (141) was only half the number of U.S. (282), but closing the gap today (156 in China vs. 180 in the",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "57e2c80e8a427e2a",
      "text": "U.S.). Korea is also more active in out- licensing activities, initiating 34 deals compared to 30 in 2022.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "711e8876fcc1cec0",
      "text": "EXHIBIT 10: U.S. and China dominated in- licensing activities",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cf5776d172f04de1",
      "text": "EXHIBIT 11: Korea has been more active in in- licensing activities",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f5fcf03c59961594",
      "text": "EXHIBIT 10: U.S. and China dominated in- licensing activities",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "82e551ee812e2e9f",
      "text": "EXHIBIT 11: Korea has been more active in in- licensing activities",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f0993113122fe5e4",
      "text": "Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "827dcd7d066c413f",
      "text": "EXHIBIT 12: U.S. and China dominated out- licensing activities",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "7dc58271d3e45a25",
      "text": "Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "2ddab2f2d98f46ed",
      "text": "EXHIBIT 13: China out- licensing closing the gap with U.S.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "dee79f131bd053d6",
      "text": "Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "4b2270c9043a0965",
      "text": "Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "ac7761fb7869616e",
      "text": "Source: Pharmcube, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "907524cef71f4f7a",
      "text": "Top 20 MNC shopping behaviors: U.S. licensees dominate as China out- licensing rises, with minimal change from 2022",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "b15fb9d5a24977fc",
      "text": "U.S. MNCs remain as top 1 licensee over the years. We set top 20 global MNCs as licensees and traced the changes in their shopping behaviors. MNCs in the U.S. remain most active in seeking license- in opportunities elsewhere, followed by a few European counterparts (Exhibit 14, Exhibit 15). This has been a longstanding strategy among leading global MNCs for several decades, serving as a way to expand their pipeline assets and mitigate the risk of sudden changes in financial performance due to loss of exclusivity (LOE).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "12ef0f1ed8382bf0",
      "text": "China has been on the rise to become a popular out- licensing country in the recent couple of years. Back in 2017, total value of out- licensing activities from China to global top 20 MNCs was a mere of US\\$ 3 Bn, but has soared to US\\$ 19 Bn in 2022 and US\\$ 39 Bn in 2025 YTD. Though total value has been increasing, we do not see much difference in the number of deals in 2025 compared to 2022, reflecting an increase in average deal value over the years",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "0e0c0575aa9d5f31",
      "text": "(Exhibit 16, Exhibit 17).",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "77a3611f96f22610",
      "text": "EXHIBIT 14. U.S. MNCs remain as top 1 licensee, followed by Europe",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3ab2f60e28bebfce",
      "text": "EXHIBIT 15. U.S. MNCs remain as top 1 licensees, followed by Europe",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "6834a72a9116ea81",
      "text": "Source: Pharmcub, Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9165ec0a78c68b16",
      "text": "Source: Pharmcub, Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "e06cbc13f48ec3d3",
      "text": "EXHIBIT 16. Top 20 MNCs favor U.S. assets, followed by Chinese assets",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b60a6a7717205d9e",
      "text": "EXHIBIT 17. Top 20 MNCs favor U.S. assets, followed by Chinese assets",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "5ed7f4ee87de40e6",
      "text": "Source: Pharmcub, Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "b5dfd5d2410e842a",
      "text": "EXHIBIT 17. Top 20 MNCs favor U.S. assets, followed by Chinese assets",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "10dfef7d880692e6",
      "text": "Source: Pharmcub, Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "1eab8e7804ae8389",
      "text": "Global licensing landscape: oncology leads, with SMD the most interested. Oncology dominates the global licensing landscape, with over 200 drugs licensed in the field, making it the most heavily transacted therapeutic area, esp. for preclinical and IND assets. This is followed by some other heated TAs, including autoimmune and CVM. In terms of modality, small molecules (37%) and monoclonal antibodies (11%) remain the most sought- after assets classes, followed by ADCs and BsAbs. (Exhibit 18, Exhibit 19).",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "1f375974f92aa0b1",
      "text": "Source: Pharmcub, Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "27c7fbabb7bbcbd2",
      "text": "Source: Pharmcub, Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9da3f5ce837158ec",
      "text": "China's out- licensing boom: record total deal value and evolving modalities. Out- licensing activity in China has surged dramatically in 1H25, with total deal value already reaching US \\(59 \\mathrm{Mn}\\) — surpassing the full- year 2024 total of US \\(47 \\mathrm{Mn}\\) . Historically, c.half of China's out- licensing agreements have been with U.S. partners, a trend that continues in 2025 with U.S.- bound deals accounting for \\(61\\%\\) of total deal value, indicating that geopolitical tensions have not yet dampened cross- border transaction momentum (Exhibit 20).",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "3f997c5278071613",
      "text": "In terms of drug modality, while ADCs and small molecules dominated the deal volume from 2022 to 2023, 2024 marked a shift as BsAbs and other novel modalities surged in deal count. This trend is further reflected in terms of upfront payment, where BsAbs took over as the modality that brought in the most upfront payments (Exhibit 21- Exhibit 22). Additionally, a new type of license deals is catching on this year: the license transfer of a \"technology platform\" instead of any specific assets. For example, CSPC and AstraZeneca announced last week a collaboration where AZ would pay US \\(110 \\mathrm{Mn}\\) upfront and US \\(5.3 \\mathrm{Bn}\\) in total to access \"CSPC's Al- driven, dual- engine efficient drug discovery platform\", which is",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "84ade17ed173f23b",
      "text": "expected to develop pre-clinical drug candidates that AZ would have the option to develop worldwide.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "6f4150a6df318091",
      "text": "Note:2025 YTD is as of June 30,2025 Source:Pharmcub, Bernstein analysis",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "f8dd10f295068bd1",
      "text": "Note:\\* Data cut off date in 2025 is on Jun.17,2025;Others Include trispecific antibody,CAR-T,etc. Source:Company disclosures,Pharmcub,Bernstein analysis",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "448439e08fcbdf54",
      "text": "Note:\\* Data cut off date in 2025 is on Jun.17,2025;Others Include trispecific antibody,CAR-T,etc. Source:Company disclosures,Pharmcub,Bernstein analysis",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "7288d0fbe23da41f",
      "text": "China's share of the global innovative drug pipeline has grown steadily in the past years and surpassed the rest of world (US, EU, Japan, Russia, Korea, and India) for the first time in 2025 (51% of global), with a focus on oncology. The rising global relevance is not just in the quantity of assets, but also quality. As Chinese players move up the innovative ladder, the number and percentage of potentially first-in-class assets in all oncology pipeline are also catching up, and closing in on the gap to rest of world levels (Exhibit 23). Increasing representation at top global medical conferences reflects the boom and growing quality of Chinese assets.",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "22dc134c3e8b8af9",
      "text": "Source:Pharmcub,Bernstein analysis",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "17409427f5902460",
      "text": "With the recent surge in China out- licensing activity, the durability of these partnerships (i.e. deals that are not fully terminated) has become a critical indicator of market maturation. Continuation rate for China out- licensing deals have strengthened considerably over the past few years, gradually converging with the benchmarks in developed markets. During 2020 and 2021, Chinese deals posted relatively weaker durability at 84.9% and 78.9% (vs. 96.1% and 93.5% for US/EU/JP/KR). The trajectory shifted in 2022, with China rebounding to 94.1% and further advancing to 97.6% in 2023, nearly matching the 99.2% level record globally. Such trend could suggest the tangible uplift in Chinese drug quality, which",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "2c1d82df586fbfbe",
      "text": "translates to more sustainable and globally viable partnerships. We note that these continuation rates seem high perhaps due to incomplete tracking in the database. Also, as time goes by, we would expect more deals to drop out.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "e7d9bb232433c186",
      "text": "EXHIBIT 24: The continuation rate of China out- licensing deals has shown a marked improvement from 2020 to 2023, closing the historical gap with development markets",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "8d5105ff87834f7e",
      "text": "Note: \\* Deal continuation rate are calculated by dividing the NO of active deals (not fully terminated) by the total number of deals Source: Pharmcub, Bernstein analysis",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "c3c3593afc0b2502",
      "text": "China biotech fundraising is showing clear signs of recovery, with the rebound most evident in HKEX. After a prolonged downturn beginning in 2022, 1H25 has recorded 6 IPOs, already surpassing the 2022 and 2024 level. Market cap raised also rebounded significantly, from HK\\$40- 70 Bn during 2022 to 2024 to HK\\$45 Bn in 1H25, alongside a major HK\\$256 Bn Hengrui listing (Exhibit 25- Exhibit 26). This recovery stands in sharp contrast to the U.S., where biotech IPOs have collapsed from 75 listings in 2021 to only 3 in 1H25, with market cap shrinking from US\\$62 Bn to US \\$3 Bn (Exhibit 27- Exhibit 28). The robust IPO momentum seen in 1H25 highlights that IPOs are re- emerging as a viable fundraising path for China biotechs, providing access to capital and growth opportunities without resorting to M&A or selling top assets.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "9fa0529da84d6742",
      "text": "Source: Bloomberg, Bernstein analysis",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "815193867af79427",
      "text": "Source: Bloomberg, Bernstein analysis",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "cfc516d387f0ea98",
      "text": "Source: Bloomberg, Bernstein analysis",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "bb36aff5614c1a60",
      "text": "Source: Bloomberg, Bernstein analysis",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "337248665027041f",
      "text": "China discount? Is the gap closing? While recent data shows a notable increase in the average upfront payment per deal for China out- licensing transactions — even surpassing the global average in 2025, we believed that such surge can be largely attributed to the uplift in upfront payments due to increase in number of assets per deal and platform- based technology deals during 2024 - 2025, which inherently causes higher average upfront payment per deal. On a per- asset basis, however, we believe that average upfront payment from China out- licensing deals will still lag behind global figures and the perceived \"China discount\" has not been fully eliminated.",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "3000d1f341fff7c4",
      "text": "EXHIBIT 29: The recent surge in upfront payment per deal for China out- licensing is primarily attributed to the uplift in upfront payments due to the increase in assets per deal and platform deals during 2024 - 2025",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "336af2ea7ee2d5a9",
      "text": "Note: 2025YTD is as of August 28th, 2025 Source: Pharmcube, Bernstein analysis",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1b7d761ace86576d",
      "text": "BERNSTEIN TICKER TABLE",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "f83945597e982b63",
      "text": "Ticker29 Aug 2025TTMRel.Adjusted EPSAdjusted P/E (x)RatingCurClosingPricePriceTargetPerf.Cur2024A2025E2026E2024A2025E2026E9926.HK (Akeso)OHKD156.00143.00204.6%CNY(0.60)1.111.80(236.1)128.679.2ONC (BeiGene)MUSD297.96259.0033.8%USD(6.12)4.298.409.36.86.11093.HK (CSPC)MHKD10.1110.7090.6%HKD0.490.370.5218.725.117.91801.HK (Innovent)OHKD96.85112.00103.9%HKD(0.06)0.821.1141.3%31.5%38.0%600276.CH (Hengrui)OCNY66.2374.0030.7%CNY1.001.431.4766.246.345.11177.HK (Sino BioPh)MHKD8.117.90133.1%CNY0.190.200.2238.837.433.99688.HK (Zai Lab)MHKD25.6028.0056.1%USD(0.26)(0.13)(0.04)(12.6)(24.5)(79.6)ABBVMUSD207.92203.00(9.7)%USD10.1011.9614.0520.617.414.8AMGNOUSD285.61335.00(30.0)%USD19.8621.0121.8414.413.613.1BMYMUSD46.8858.00(22.0)%USD1.136.516.3041.47.27.4LLYOUSD731.961,100.00(38.4)%USD12.9922.8430.1556.332.024.3GILDOUSD112.56135.0025.4%USD4.618.168.8724.413.812.7MRKMUSD83.2195.00(45.4)%USD7.648.939.5510.99.38.7PFEMUSD24.6030.00(30.6)%USD3.113.023.087.98.28.0AZ.N.LNOGBp11,81018,000(22.2)%USD8.219.2611.2619.417.214.2BAYN.GRMEUR27.9230.00(10.8)%EUR5.054.514.895.56.25.7IPN.FPOEUR117.90148.00(3.1)%EUR10.2710.1210.9111.511.710.8MRK.GRMEUR107.10138.00(49.0)%EUR8.638.129.5312.413.211.2NOVN.SWOCHF101.54108.00(12.0)%USD7.818.819.2416.214.413.7NOVOB.DCMDKK358.80620.00(72.5)%DKK25.3228.4934.3714.212.610.4ROG.SWOCHF261.00345.00(20.0)%CHF18.8021.0022.7013.912.411.5SAN.FPOEUR85.36119.00(27.6)%EUR7.127.668.9412.011.19.6UCB.BBMEUR200.40197.0011.0%EUR4.867.199.5341.227.921.0GSK.LNOGBp1,459.502,170.00(23.4)%GBp157.36166.47200.109.38.87.3ASIAX1,495.91SPX6,501.86EDM1,479.43",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "55f15eb9fa9ec340",
      "text": "O - Outperform, M - Market-Perform, U - Underperform, NR - Not Rated, CS - Covered Suspended",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "3681964df431c469",
      "text": "9926.HK, ONC, 1093.HK, 1801.HK, 600276.CH, 1177.HK, 9688.HK estimate is Reported EPS; 9926.HK, 1093.HK, 600276.CH, 1177.HK, 9688.HK valuation is",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "ff716968e9b47c1c",
      "text": "Reported P/E (x); ONC valuation is EV/Sales (x); 1801.HK valuation is Gross Profit CAGR; 1093.HK base year is 2023;",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "d09d17acd2e90fd4",
      "text": "Source: Bloomberg, Bernstein estimates and analysis.",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "e1b6b08b5e3f65f7",
      "text": "References to \"Bernstein\" or the \"Firm\" in these disclosures relate to the following entities: Bernstein Institutional Services LLC (April 1, 2024 onwards), Sanford C. Bernstein & Co., LLC (pre April 1, 2024), Bernstein Autonomous LLP, BSG France S.A. (April 1, 2024 onwards), Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private Limited (SEBI registration no. INH000006378), Sanford C. Bernstein (Singapore) Private Limited and Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社).",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "bea204c9e47d4e94",
      "text": "On April 1, 2024, Société Générale (SG) and AllianceBernstein, L.P. (AB) completed a transaction that created a new joint venture in which their respective cash equities and research businesses operate in a new business combination. Although their respective ownership percentages in the joint venture differ between North America and the rest of the world, the creation, production and publication of research is handled collaboratively on a global basis across the two research brands, \"Bernstein\" and \"Autonomous\". Unless specifically noted otherwise, for purposes of these disclosures, references to Bernstein's \"affiliates\" relate to both SG and AB and their respective affiliates.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "842e8d5271ae9982",
      "text": "This research publication covers six or more companies. For valuation methodology and other company disclosures: Please visit: https://bernstein- autonomous.bluematrix.com/sellside/Disclosures.action. Or, you can also write to the Director of Compliance, Bernstein Institutional Services LLC, 245 Park Avenue, New York, NY 10167.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "a300c7f2a839aaad",
      "text": "This research publication covers six or more companies. For risks and other company disclosures: Please visit: https://bernstein- autonomous.bluematrix.com/sellside/Disclosures.action. Or, you can also write to the Director of Compliance, Bernstein Institutional Services LLC, 245 Park Avenue, New York, NY 10167.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "24069f8a10dc095f",
      "text": "The Bernstein brand rates stocks based on forecasts of relative performance for the next 12 months versus the S&P 500 for stocks listed on the U.S. and Canadian exchanges, versus the Bloomberg Europe Developed Markets Large and Mid Cap Price Return Index (EDM) for stocks listed on the European exchanges and emerging markets exchanges outside of the Asia Pacific region, versus the Bloomberg Japan Large and Mid Cap Price Return Index USD (JP) for stocks listed on the Japanese exchanges, and versus the Bloomberg Asia ex- Japan Large and Mid Cap Price Return Index (ASIAX) for stocks listed on the Asian (ex- Japan) exchanges - unless otherwise specified.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "68c89e0d78266b61",
      "text": "The Bernstein brand has three categories of ratings:",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "e2f8d460f7f7187c",
      "text": "- Outperform: Stock will outpace the market index by more than 15 pp- Market-Perform: Stock will perform in line with the market index to within +/-15 pp- Underperform: Stock will trail the performance of the market index by more than 15 pp",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "8bf26fd50bbc0d2b",
      "text": "Coverage Suspended: Coverage of a company under the Bernstein research brand has been suspended. Ratings and price targets are suspended temporarily, are no longer current, and should therefore not be relied upon.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "53adf34880331a4f",
      "text": "Not Rated: A rating assigned when the stock cannot be accurately valued, or the performance of the company accurately predicted, at the present time. The covering analyst may continue to publish research reports on the company to update investors on events and developments.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "f7850f57d28e0e55",
      "text": "Not Covered (NC) denotes companies that are not under coverage.",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "27f237d40d6fc4c2",
      "text": "The Autonomous brand rates stocks as indicated below. As our benchmarks we use the Bloomberg Europe 500 Banks And Financial Services Index (BEBANKS) and Bloomberg Europe Dev Mkt Financials Large and Mid Cap Price Ret Index EUR (EDMFI) index for developed European banks and Payments, the Bloomberg Europe 500 Insurance Index (BEINSUR) for European insurers, the S&P 500 and S&P Financials for US banks and Payments coverage, S5LIFE for US Insurance, the S&P Insurance Select Industry (SPSIINS) for US Non-Life Insurers coverage, and the Bloomberg Emerging Markets Financials Large, Mid and Small Cap Price Return Index (EMLSF) for emerging market banks and insurers and Payments. Ratings are stated relative to the sector (not the market).",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8f92e82949c839eb",
      "text": "The Autonomous brand has three categories of ratings:",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "085d921962acda2b",
      "text": "- Outperform (OP): Stock will outpace the relevant index by more than 10 pp- Neutral (N): Stock will perform in line with the market index to within +/-10 pp- Underperform (UP): Stock will trail the performance of the relevant index by more than 10 pp",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "98530e21675be338",
      "text": "Coverage Suspended: Coverage of a company under the Bernstein research brand has been suspended. Ratings and price targets are suspended temporarily, are no longer current, and should therefore not be relied upon.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8b01a81456f6dc39",
      "text": "Not Rated: A rating assigned when the stock cannot be accurately valued, or the performance of the company accurately predicted, at the present time. The covering analyst may continue to publish research reports on the company to update investors on events and developments.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "091e77777baf345a",
      "text": "Those denoted as 'Feature' (e.g., Feature Outperform FOP, Feature Under Outperform FUP) are our core ideas. Not Covered (NC) denotes companies that are not under coverage.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3a6dccf8542a07c8",
      "text": "For both brands, recommendations are based on a 12- month time horizon.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "4b2efe949fa5e696",
      "text": "DISTRIBUTION OF EQUITY RATINGS/INVESTMENT BANKING SERVICES",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "15ed212e76358309",
      "text": "RatingMarket Abuse Regulation (MAR) and FINRA Rule 2241 classificationCountPercentCount*Percent*OutperformBUY58551.27%11018.80%Market-Perform (Bernstein Brand)HOLD40735.67%7618.67%Neutral (Autonomous Brand)UnderperformSELL14913.06%2013.42%",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "450142d9f1567d52",
      "text": "\\* These figures represent the number and percentage of companies in each category to whom affiliates of Bernstein and Autonomous provided investment banking services. As of June 30, 2025. All figures are updated quarterly.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "06a7fd98559a93d7",
      "text": "Bernstein Autonomous LLP or BSG France SA, beneficially, has either a net long or short position of \\(0.5\\%\\) or more of the total issued share capital of a class of common equity securities of the following MiFID eligible securities: Eli Lilly & Co.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "dd666ac692e3ef39",
      "text": "Bernstein and/or affiliates have received compensation for investment banking services in the past twelve months from AbbVie Inc.",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "3161f9e55e2095f6",
      "text": "Bernstein and/or affiliates have received compensation for investment banking services in the past twelve months from Gilead Sciences Inc.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "42cb12ee70f24a93",
      "text": "Bernstein and/or affiliates have received compensation for investment banking services in the past twelve months from Ipsen.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "5ed75fd6eab4d5d2",
      "text": "Bernstein and/or affiliates have received compensation for investment banking services in the past twelve months from Merck KGaA.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "37c4dbee2cd80a3a",
      "text": "Bernstein and/or affiliates have received compensation for investment banking services in the past twelve months from Sanofi.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "d47bf9659a383be6",
      "text": "Bernstein and/or affiliates have received compensation for non- investment banking securities- related products or services in the previous twelve months from the following clients: AbbVie Inc, Amgen Inc, Bristol- Myers Squibb Co, Gilead Sciences Inc, Merck & Co Inc, Pfizer Inc, AstraZeneca PLC, Bayer AG, Ipsen, Novartis AG, Novo Nordisk A/S, Roche Holding AG and Sanofi.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "0dc331f7cb9eb67f",
      "text": "An affiliate of Bernstein has received compensation for non- investment banking securities- related products or services in the previous twelve months from the following clients: Gilead Sciences Inc, Merck & Co Inc, Pfizer Inc, Bayer AG, Merck KGaA and Roche Holding AG.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "26153f8bc0e684d0",
      "text": "Bernstein has received compensation for non- investment banking securities- related products or services in the previous twelve months from the following clients: Novartis AG and Novo Nordisk A/S.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "c40910383768883a",
      "text": "Bernstein and/or affiliates expect to receive or intend to seek compensation for investment banking services in the next three months from Sanofi.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "44211f87ace80262",
      "text": "Affiliates of Bernstein managed or co- managed in the past twelve months a public offering of securities of AbbVie Inc, Gilead Sciences Inc, Ipsen and Sanofi.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "bcd59d252db80ebb",
      "text": "Bernstein and/or affiliates had an investment banking client relationship during the past twelve months with AbbVie Inc, Gilead Sciences Inc, Ipsen, Merck KGaA and Sanofi.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f03c708b9657a037",
      "text": "Certain affiliates of Bernstein act as market maker or liquidity provider in the equities securities of: AbbVie Inc, Amgen Inc, Bristol- Myers Squibb Co, Eli Lilly & Co, Gilead Sciences Inc, Merck & Co Inc, Pfizer Inc, AstraZeneca PLC, Bayer AG, Ipsen, Merck KGaA, Novartis AG, Novo Nordisk A/S, Roche Holding AG, Sanofi, UCB SA and GSK plc.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "5e4c29d2a652add1",
      "text": "Certain affiliates of Bernstein act as market maker or liquidity provider in the debt securities of: AbbVie Inc, Amgen Inc, Bristol- Myers Squibb Co, Eli Lilly & Co, Gilead Sciences Inc, Merck & Co Inc, AstraZeneca PLC, Ipsen, Novartis AG, Novo Nordisk A/S, Sanofi and UCB SA.",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "1f385ac841ea1991",
      "text": "The legal entity(ies) employing the analyst(s) listed in this report, and their location, can be determined by the country code of their phone number, as follows:",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "2e3b20a2d514efbd",
      "text": "+1 Bernstein Institutional Services LLC; New York, New York, USA+44 Bernstein Autonomous LLP; London UK+33 BSG France S.A.; Paris, France+34 BSG France S.A.; Madrid, Spain+41 Bernstein Autonomous LLP; Geneva, Switzerland+49 BSG France S.A.; Frankfurt, Germany+91 Sanford C. Bernstein (India) Private Limited; Mumbai, India",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "795a0aef2749eb2c",
      "text": "+852 Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司; Hong Kong, China",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "74e9fb19e67237e3",
      "text": "+65 Sanford C. Bernstein (Singapore) Private Limited; Singapore",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "22f4862233fa7e65",
      "text": "+81 Sanford C. Bernstein Japan KK; Tokyo, Japan",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "cab54259fef20957",
      "text": "Where this report has been prepared by research analyst(s) employed by a non- US affiliate, such analyst(s), is/are (unless otherwise expressly noted below) not registered as associated persons of Bernstein Institutional Services LLC or any other SEC- registered broker- dealer and are not licensed or qualified as research analysts with FINRA. Accordingly, such analyst(s) may not be subject to FINRA's restrictions regarding (among other things) communications by research analysts with a subject company, interactions between research analysts and investment banking personnel, participation by research analysts in solicitation and marketing activities relating to investment banking transactions, public appearances by research analysts, and trading securities held by a research analyst account.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "6ca0bba4800a6129",
      "text": "Each research analyst listed in this report, who is primarily responsible for the preparation of the content of this report, certifies that all of the views expressed in this publication accurately reflect that analyst's personal views about any and all of the subject securities or issuers and that no part of that analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views in this publication.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "196cc8a32a6757ac",
      "text": "It is at the sole discretion of the Firm as to when to initiate, update and cease research coverage. The Firm has established, maintains and relies on information barriers to control the flow of information contained in one or more areas (i.e., the private side) within the Firm, and into other areas, units, groups or affiliates (i.e., public side) of the Firm.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "af724e1ef1faf592",
      "text": "Separate branding is maintained for \"Bernstein\" and \"Autonomous\" research products.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "3fab59ca554eebd9",
      "text": "- Bernstein produces a number of different types of research products including, among others, fundamental analysis and quantitative analysis under both the \"Autonomous\" and \"Bernstein\" brands. Recommendations contained within one type of research product may differ from recommendations contained within other types of research products, whether as a result of differing time horizons, methodologies or otherwise. Furthermore, views or recommendations within a research product issued under one brand may differ from views or recommendations under the same type of research product issued under the other brand. The Research Ratings System for the two brands and other information related to those Rating Systems are included in the previous section.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "60d2556663794fed",
      "text": "- Autonomous operates as a separate business unit within the following entities: Bernstein Institutional Services LLC, Bernstein Autonomous LLP, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 and Sanford C. Bernstein (India) Private Limited. For information relating to \"Autonomous\" branded products (including certain Sales materials) please visit: www.autonomous.com. For information relating to Bernstein branded products please visit: www.bernsteinresearch.com.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "a0401ee1c8e06bb0",
      "text": "Analysts are compensated based on aggregate contributions to the research franchise as measured by account penetration, productivity and proactivity of investment ideas. No analysts are compensated based on performance in, or contributions to, generating investment banking revenues.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "a63406f02ed7564b",
      "text": "This report has been produced by an independent analyst as defined in Article 3 (1)(34)(i) of EU 596/2014 Market Abuse Regulation (\"MAR\") and the same article of MAR as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "2cf244f6060d1eab",
      "text": "To our readers in the United States: Bernstein Institutional Services LLC, a broker- dealer registered with the U.S. Securities and Exchange Commission (\"SEC\") and a member of the U.S. Financial Industry Regulatory Authority, Inc. (\"FINRA\") is distributing this publication in the United States and accepts responsibility for its contents. Where this material contains an analysis of debt product(s), such material is intended only for institutional investors and is not subject to the US independence and disclosure standards applicable to debt research prepared for retail investors.",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "26bd7d64a040c9d2",
      "text": "Bernstein Institutional Services LLC may act as principal for its own account or as agent for another person (including an affiliate) in sales or purchases of any security which is a subject of this report. This report does not purport to meet the objectives or needs of any specific individuals, entities or accounts.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "fda589174f81935b",
      "text": "To our readers in Canada: If this publication pertains to a Canadian domiciled company, it is being distributed in Canada by Sanford C. Bernstein (Canada) Limited, which is licensed and regulated by the Canadian Investment Regulatory Organization. If the publication pertains to a non- Canadian domiciled company, it is being distributed by Bernstein Institutional Services LLC, which is licensed and regulated by both the SEC and FINRA, into Canada under the International Dealers Exemption.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e40fd1e69c910552",
      "text": "This document may not be passed onto any person in Canada unless that person qualifies as \"permitted client\" as defined in Section 1.1 of NI 31- 103.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "f69b9ec935f8a117",
      "text": "To our readers in Brazil: This report has been prepared by Bernstein Institutional Services LLC, and Banco BTG Pactual S.A. (\"BTG\") is responsible for the distribution of this report in Brazil.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "9a96b472b1ae724b",
      "text": "To readers in the United Kingdom: This publication has been issued or approved for issue in the United Kingdom by Bernstein Autonomous LLP, authorised and regulated by the Financial Conduct Authority and located at 60 London Wall, London EC2M 5SH, +44 (0)20- 7170- 5000. Registered in England & Wales No OC343985.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "e4e8ab2bc72c8d78",
      "text": "This document is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the \"Financial Promotion Order\"), (ii) are persons falling within Article 49(2)(a) to (d) (\"high net worth companies, unincorporated associations, etc.\") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as \"relevant persons\"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "0dc51387be8e365e",
      "text": "To our readers in the member states of the EEA: This publication is being distributed by BSG France SA, which is authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and Autorité des Marchés Financiers (AMF).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "9898721e02bed0c0",
      "text": "To our readers in Hong Kong: This publication is being distributed in Hong Kong by Sanford C. Bernstein (Hong Kong) Limited, which is licensed and regulated by the Hong Kong Securities and Futures Commission (Central Entity No. AXC846) to carry out Type 4 (Advising on Securities) regulated activities and subject to the licensing conditions mentioned in the SFC Public Register (https://www.sfc.hk/publicregWeb/corp/AXC846/details)). This publication is solely for professional investors, as defined in the Securities and Futures Ordinance (Cap. 571).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "6514ec79ba80c79b",
      "text": "To our readers in Singapore: This publication is being distributed in Singapore by Sanford C. Bernstein (Singapore) Private Limited, only to accredited investors or institutional investors, as defined in the Securities and Futures Act 2001 of Singapore (\"SFA\"). Recipients in Singapore should contact Sanford C. Bernstein (Singapore) Private Limited in respect of matters arising from, or in connection with, this publication. Sanford C. Bernstein (Singapore) Private Limited is regulated by the Monetary Authority of Singapore and licensed under the SFA as a capital markets services licence holder for dealing in capital markets products that are securities and collective investment schemes and an exempt financial adviser for advising on, issuing and promulgating analyses and reports on securities. Sanford C. Bernstein (Singapore) Private Limited is registered in Singapore with Company Registration No. 20213710W and located at One Raffles Quay, #27- 11 South Tower, Singapore 048583, +65- 6230- 4612.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "8101a6deab71b537",
      "text": "To our readers in the People's Republic of China: The securities referred to in this document are not being offered or sold and may not be offered or sold, directly or indirectly, in the People's Republic of China (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan, the \"PRC\") in contravention of any applicable laws of the PRC.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "173de854f787b813",
      "text": "This document does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC to any person to whom it is unlawful to make the offer or solicitation in the PRC.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "4a7d3cfa49046619",
      "text": "We do not represent that this document may be lawfully distributed, or that any securities may be lawfully offered, in compliance with any applicable registration or other requirements in the PRC, or pursuant to an exemption available thereunder, or assume any responsibility for facilitating any such distribution or offering. In particular, no action has been taken by us which would permit a public offering of any securities or distribution of this document in the PRC. Accordingly, the securities are not being offered",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "ebeb20d3ce22e97e",
      "text": "or sold within the PRC by means of this document or any other document. Neither this document nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with any applicable laws and regulations.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "5483c6330b8cb24b",
      "text": "To our readers in Japan: This publication is being distributed in Japan by Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社), which is registered in Japan as a Financial Instruments Business Operator with the Kanto Local Finance Bureau (registration number: The Director- General of Kanto Local Finance Bureau (FIBO) No.3387) and regulated by the Financial Services Agency. It is also a member of Japan Investment Advisers Association. This publication is solely for qualified institutional investors in Japan only, as defined in Article 2, paragraph (3), items (i) of the Financial Instruments and Exchange Act.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "a4da708ccd1fa9e7",
      "text": "For the institutional client readers in Japan who have been granted access to the Bernstein website by Daiwa Securities Group Inc. (\"Daiwa\"), your access to this document should not be construed as meaning that Bernstein is providing you with investment advice for any purposes. Whilst Bernstein has prepared this document, your relationship is, and will remain with, Daiwa, and Bernstein has neither any contractual relationship with you nor any obligations towards you.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "06400d6def83cd4c",
      "text": "To our readers in Australia: Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 is responsible for distributing research in Australia. It is regulated by the Securities and Exchange Commission under U.S. laws, by the Financial Conduct Authority under U.K. laws, which differs from Australian laws. Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 is exempt from the requirement to hold an Australian financial services license under the Corporations Act 2001 in respect of the provision of the following financial services to wholesale clients:",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "a63ffd58b277eeef",
      "text": "- providing financial product advice;- dealing in a financial product;- making a market for a financial product; and- providing a custodial or depository service.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "42246648c9e56bd7",
      "text": "To our readers in India: This publication is being distributed in India by Sanford C. Bernstein (India) Private Limited (SCB India) which is licensed and regulated by Securities and Exchange Board of India (\"SEBI\") as a research analyst entity under the SEBI (Research Analyst) Regulations, 2014, having registration no. INH000006378 and as a stock broker having registration no. INZ000213537. SCB India is currently engaged in the business of providing research and stock broking services. Please refer to www.bernsteinresearch.in for more information.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "04e68316a73f28ba",
      "text": "- SCB India is a Private limited company incorporated under the Companies Act, 2013, on April 12, 2017 bearing corporate identification number U65999MH2017FTC293762, and registered office at Level 3A, 4th Floor, First International Financial Centre, Plot Nos C-54 and C-55, G Block, Near CBI Office, Bandra Kurla Complex, Bandra (East), Mumbai 400098, Maharashtra, India (Phone No: +91-22-68421401).",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "9d2723d4b6bffd46",
      "text": "- SCB India does not have any disciplinary history as on the date of this report.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "7628afb33a464136",
      "text": "- Except as noted above, SCB India and/or its Associates (i.e., affiliates/group companies), the Research Analysts authoring this report, and their relatives",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "e26738a8f0787f86",
      "text": "- do not have any financial interest in the subject company- do not have actual/beneficial ownership of one percent or more in securities of the subject company;- is not engaged in any investment banking activities for Indian companies, as such;- have not managed or co-managed a public offering in the past twelve months for any Indian companies;- have not received any compensation for investment banking services or merchant banking services from the subject company in the past 12 months;",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "4500e16b58a9939a",
      "text": "- have not received compensation for brokerage services from the subject company in the past twelve months;",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "54eb23b718a810fd",
      "text": "- have not received any compensation or other benefits from the subject company or third party related to the specific recommendations or views in this report; and",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "052194638978206d",
      "text": "- do not currently, but may in the future, act as a market maker in the financial instruments of the companies covered in the report.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "74a1d7e566af601f",
      "text": "- do not have any conflict of interest in the subject company as of the date of this report.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "f7379c70b5e53dec",
      "text": "- Except as noted above, the subject company has not been a client of SCB India during twelve months preceding the date of distribution of this research report. Neither SCB India nor its Associates (i.e., affiliates/group companies) have received compensation for products or services other than investment banking, merchant banking or brokerage services from the subject company in the past twelve months.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "38d5acb37330ba3e",
      "text": "- The principal research analyst(s) who prepared this report, members of the analysts' team, and members of their households are not an officer, director, employee or advisory board member of the companies covered in the report.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "c3f702aaa355b30c",
      "text": "- The investor charter of SCB India is available on its website and may be accessed at Sanford C. Bernstein (India) Private Limited (bernsteinresearch.in)",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "3315b505c441941c",
      "text": "- Disclaimer: Registration granted by SEBI, and certification from NISM, is in no way a guarantee of performance of the intermediary or provide any assurance of returns to investors. Investments in securities market are subject to market risks. Read all the related documents carefully before investing.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "51d30b56ac565434",
      "text": "To our readers in Switzerland: This document is provided in Switzerland by or through Bernstein Autonomous LLP, and is provided only to qualified investors as defined in article 10 of the Swiss Collective Investment Scheme Act (\"CISA\") and related provisions of the Collective Investment Scheme Ordinance and in strict compliance with applicable Swiss law and regulations. The products mentioned in this document may not be suitable for all types of investors. This document is based on the Directives on the Independence of Financial Research issued by the Swiss Bankers Association (SBA) in January 2008.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "00027f2ce516858b",
      "text": "To our readers in the Middle East: Bernstein Autonomous LLP, DIFC branch has its principal office at Gate Village 06, DIFC, Dubai, UAE. Bernstein Autonomous LLP, DIFC branch is regulated by the Dubai Financial Services Authority (DFSA) with the registration number F008549 and is provisioned for Arranging Deals in Investments and Advising on Financial Products. All communications and services are directed at Professional Clients and Market Counterparties only (as defined in the DFSA rulebook). Persons other than Professional Clients and Market Counterparties, such as Retail Clients, are not the intended recipients of our communications or services.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "4baae62ea5c29944",
      "text": "All research publications are disseminated to our clients through posting on the firm's password protected websites, bernsteinresearch.com and autonomous.com. Certain, but not all, research publications are also made available to clients through third- party vendors or redistributed to clients through alternate electronic means as a convenience.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "4f02daeb4c1a0ed0",
      "text": "This publication has been published and distributed in accordance with the Firm's policy for management of conflicts of interest in investment research, a copy of which is available from Bernstein Institutional Services LLC, Director of Compliance, 245 Park Avenue, New York, NY 10167. Additional disclosures and information regarding Bernstein's business are available on our website www.bernsteinresearch.com.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "8606d0bd4019f551",
      "text": "The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors where that permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may be permitted by law. This publication is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject any of the entities referenced herein or any of their subsidiaries or affiliates to any registration or licensing requirement within such jurisdiction. This publication is based upon public sources",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "f6e1a770bb59fbb4",
      "text": "we believe to be reliable, but no representation is made by us that the publication is accurate or complete. We do not undertake to advise you of any change in the reported information or in the opinions herein. This publication was prepared and issued by entity referred to herein for distribution to eligible counterparties or professional clients. This publication is not an offer to buy or sell any security, and it does not constitute investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with their professional advisors in light of their specific circumstances. The value of investments may fluctuate, and investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to exchange rate movements. Information about past performance of an investment is not necessarily a guide to, indicator of, or assurance of, future performance.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "347fe8b49a61713a",
      "text": "This report is directed to and intended only for our clients who are \"eligible counterparties\", \"professional clients\", \"institutional investors\" and/or \"professional investors\" as defined by the aforementioned regulators, and must not be redistributed to retail clients as defined by the aforementioned regulators. Retail clients who receive this report should note that the services of the entities noted herein are not available to them and should not rely on the material herein to make an investment decision. The result of such act will not hold the entities noted herein liable for any loss thus incurred as the entities noted herein are not registered/ authorised/ licensed to deal with retail clients and will not enter into any contractual agreement/arrangement with retail clients. This report is provided subject to the terms and conditions of any agreement that the clients may have entered into with the entities noted herein. All research reports are disseminated on a simultaneous basis to eligible clients through electronic publication to our client portal. The information is private and confidential and for the use of the clients only.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "f5f7eb8eae0599ca",
      "text": "This report has been prepared for information purposes only and is based on current public information that we consider reliable, but the entities noted herein do not warrant or represent (express or implied) as to the sources of information or data contained herein are accurate, complete, not misleading or as to its fitness for the purpose intended even though the entities noted herein rely on reputable or trustworthy data providers, it should not be relied upon as such. Opinions expressed are the author(s)' current opinions as of the date appearing on the material only and we do not undertake to advise you of any change in the reported information or in the opinions herein.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "759d342a65d4b251",
      "text": "This publication was prepared and issued by the entity referred to herein for distribution to eligible counterparties or professional clients. The information in this report is intended for general circulation and does not constitute an offer to buy or sell any security, investment, legal or tax advice nor a personal recommendation, as defined by any of the aforementioned regulators. It does not take into account the particular investment objectives, financial situations, or needs of individual investors. The report has not been reviewed by any of the aforementioned regulators and does not represent any official recommendation from the aforementioned regulators. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with advice sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any recipient of the recommendation, before the recipient makes a commitment to purchase the investment product.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "88a4d841a7842eb7",
      "text": "The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The information in this report does not constitute, or form part of, any offer to sell or issue, or any offer to purchase or subscribe for shares, or to induce engage in any other investment activity. The value of any securities or financial instruments mentioned in this report may fluctuate subject to market conditions. Information about past performance of an investment is not necessarily a guide to, indicative of, or assurance of future performance. Estimates of future performance mentioned by the research analyst in this report are based on assumptions that may not be realized due to unforeseen factors like market volatility/fluctuation. In relation to securities or financial instruments denominated in a foreign currency other than the clients' home currency, movements in exchange rates will have an effect on the value, either favorable or unfavorable. Before acting on any recommendations in this report, recipients should consider the appropriateness of investing in the subject securities or financial instruments mentioned in this report and, if necessary, seek for independent professional advice.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "8e7d9b0cc342e7c0",
      "text": "The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors where that permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject the entities noted herein to any regulation or licensing requirement within such jurisdiction.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "ca56311edf4f6668",
      "text": "extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "38bda5d029a9a4bc",
      "text": "No part of this material may be reproduced, distributed or transmitted or otherwise made available without prior consent of the entities noted herein. Copyright Bernstein Institutional Services LLC Bernstein Autonomous LLP, BSG France S.A., Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private Limited (SEBI registration no. INH000006378), Sanford C. Bernstein (Singapore) Private Limited and Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社). All rights reserved. The trademarks and service marks contained herein are the property of their respective owners. Any unauthorized use or disclosure is strictly prohibited. The entities noted herein may pursue legal action if the unauthorized use results in any defamation and/or reputational risk to the entities noted herein and research published under the Bernstein and Autonomous brands.",
      "page": 16,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "92189241639fdfe4",
      "name": "AbbVie Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "af0234deee25916b",
      "name": "Adjusted EPS",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7e2d4425303bea59",
      "name": "Administrative Regions",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6afac77b7140b4ce",
      "name": "Advisers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "aa4b9a172f427744",
      "name": "Amgen Inc",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bf450f9d7cbb2e1d",
      "name": "Arranging Deals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e47fcc05cddb7f74",
      "name": "As Chinese",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2ebc1f6a39f03ec8",
      "name": "Asia Pacific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "12195026261f523b",
      "name": "AstraZeneca PLC",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "18ff676d9d8cf555",
      "name": "Autonomous Brand",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c160d65049f4dfd5",
      "name": "Autonomous LLP",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5a165af17b571df3",
      "name": "BSG France",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f0c4286f4d23d3fd",
      "name": "Banco BTG",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dc2c783d2ec3346b",
      "name": "Bandra Kurla",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "abef6f4f10fd10f6",
      "name": "Banks And",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "a99050f978a6bc4a",
      "name": "Bayer AG",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2de3ec6fb4398605",
      "name": "Bernstein & Co",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "02c62a0dceca70db",
      "name": "Bernstein Autonomous",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d6ff22152f52aa09",
      "name": "Bernstein Brand",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "ed70a6a16109e9ba",
      "name": "Bernstein EU",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "bar",
        "title": "Market Cap @ IPO for China Pharma and Biotech Companies on HKEX (HK$ Bn)",
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2021",
              "2022",
              "2023",
              "2024",
              "2025YTD"
            ]
          },
          "y": {
            "unit": "HK$ Bn",
            "range": {
              "min": 0,
              "max": 300
            }
          }
        },
        "series": [
          {
            "name": "Biotech",
            "unit": "HK$ Bn",
            "values": [
              136,
              45,
              69,
              39,
              45
            ]
          },
          {
            "name": "Pharma",
            "unit": "HK$ Bn",
            "values": [
              45,
              3,
              17,
              17,
              256
            ]
          }
        ],
        "figure_id": "e6a8b1d55e99ec69",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "bar",
        "title": "Top Acquirer Countries for M&A in 2022 (Sum of TDV, US$ Bn)",
        "page": 3,
        "axes": {
          "x": {
            "type": "value",
            "labels": [
              "0",
              "20",
              "40",
              "60",
              "80"
            ]
          },
          "y": {
            "unit": "country",
            "range": {
              "min": null,
              "max": null
            }
          }
        },
        "series": [
          {
            "name": "Acquirer Countries",
            "unit": "US$ Bn",
            "values": [
              {
                "country": "U.S.",
                "value": 67.8
              },
              {
                "country": "Europe",
                "value": 12.8
              },
              {
                "country": "Japan",
                "value": 6.5
              },
              {
                "country": "China",
                "value": 1.3
              },
              {
                "country": "Others",
                "value": 2.4
              }
            ]
          }
        ],
        "figure_id": "57a47ae6bdec9202",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "bar",
        "title": "Market Cap @ IPO for US Biotechs (US$ Bn)",
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2021",
              "2022",
              "2023",
              "2024",
              "2025YTD"
            ]
          },
          "y": {
            "unit": "US$ Bn",
            "range": {
              "min": 0,
              "max": 70
            }
          }
        },
        "series": [
          {
            "name": "Market Cap",
            "unit": "US$ Bn",
            "values": [
              62,
              6,
              6,
              13,
              3
            ]
          }
        ],
        "figure_id": "330e6945e0dd8260",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "bar",
        "title": "Deal continuation rate",
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2020",
              "2021",
              "2022",
              "2023"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "CN out-licensing",
            "unit": "%",
            "values": [
              85,
              79,
              94,
              98
            ]
          },
          {
            "name": "US/EU/JP/KR deals",
            "unit": "%",
            "values": [
              96,
              94,
              98,
              99
            ]
          }
        ],
        "figure_id": "49e053f725da3215",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "combo",
        "title": "China out-licensing activity: deal count, total deal value, and total upfront payment (for total deal value ≥US$500 Mn deals)",
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2021",
              "2022",
              "2023",
              "2024",
              "2025 1H"
            ]
          },
          "y": {
            "unit": "US$ Bn",
            "range": {
              "min": 0,
              "max": 70
            }
          }
        },
        "series": [
          {
            "name": "Total deal value",
            "unit": "US$ Bn",
            "values": [
              12.6,
              26.6,
              38.8,
              47.4,
              58.7
            ]
          },
          {
            "name": "Total upfront payment",
            "unit": "US$ Bn",
            "values": [
              1.5,
              0.9,
              2.7,
              3.0,
              2.7
            ]
          },
          {
            "name": "Deal count",
            "unit": null,
            "values": [
              8,
              21,
              28,
              32,
              25
            ]
          }
        ],
        "figure_id": "3df13f78835d16fa",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "combo",
        "title": "Global licensing activity: TDV, upfront payment, and deal count (US$ Bn)",
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2018",
              "2019",
              "2020",
              "2021",
              "2022",
              "2023",
              "2024",
              "2025 YTD"
            ]
          },
          "y": {
            "unit": "US$ Bn",
            "range": {
              "min": 0,
              "max": 200
            }
          }
        },
        "series": [
          {
            "name": "Total Value (LHS)",
            "unit": "US$ Bn",
            "values": [
              81,
              100,
              145,
              143,
              165,
              165,
              174,
              163
            ]
          },
          {
            "name": "Upfront payment (LHS)",
            "unit": "US$ Bn",
            "values": [
              9,
              16,
              18,
              13,
              16,
              17,
              15,
              13
            ]
          },
          {
            "name": "Deal Count (RHS)",
            "unit": null,
            "values": [
              550,
              570,
              870,
              780,
              720,
              700,
              730,
              550
            ]
          }
        ],
        "figure_id": "6f870cf87b036cbe",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "bar",
        "title": "Upfront payments (US$Mn) of China innovative drugs out-licensed overseas since 2022 (≥US$500 Mn) by modality",
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2022",
              "2023",
              "2024",
              "2025 1H"
            ]
          },
          "y": {
            "unit": "US$Mn",
            "range": {
              "min": 0,
              "max": 3500
            }
          }
        },
        "series": [
          {
            "name": "ADCs",
            "unit": "US$Mn",
            "values": [
              257,
              1587,
              392,
              322
            ]
          },
          {
            "name": "Small molecules",
            "unit": "US$Mn",
            "values": [
              506,
              762,
              591,
              480
            ]
          },
          {
            "name": "mAb",
            "unit": "US$Mn",
            "values": [
              0,
              0,
              1389,
              1325
            ]
          },
          {
            "name": "BsAb",
            "unit": "US$Mn",
            "values": [
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "RNAi",
            "unit": "US$Mn",
            "values": [
              0,
              95,
              185,
              0
            ]
          },
          {
            "name": "Platform",
            "unit": "US$Mn",
            "values": [
              0,
              0,
              0,
              110
            ]
          },
          {
            "name": "Others",
            "unit": "US$Mn",
            "values": [
              60,
              100,
              415,
              385
            ]
          }
        ],
        "figure_id": "72feb7647b628ca5",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "combo",
        "title": "No. potential FIC oncology assets entering into clinical trials by year",
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2021",
              "2022",
              "2023",
              "2024",
              "2025 YTD"
            ]
          },
          "y": {
            "unit": "count",
            "range": {
              "min": 0,
              "max": 350
            }
          },
          "y2": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 50
            }
          }
        },
        "series": [
          {
            "name": "US, EU, JP, RU, KR, IN",
            "unit": "count",
            "values": [
              100,
              155,
              125,
              140,
              48
            ]
          },
          {
            "name": "China",
            "unit": "count",
            "values": [
              80,
              95,
              85,
              145,
              50
            ]
          },
          {
            "name": "China % of total oncology",
            "unit": "%",
            "values": [
              22,
              23,
              24,
              32,
              22
            ]
          },
          {
            "name": "Global % of total oncology",
            "unit": "%",
            "values": [
              28,
              39,
              39,
              42,
              28
            ]
          }
        ],
        "figure_id": "6869b3e08e822471",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "bar",
        "title": "Top In-license Countries in 2022 by # Deals",
        "page": 3,
        "axes": {
          "x": {
            "type": "value",
            "unit": "Deals",
            "range": {
              "min": 0,
              "max": 250
            }
          },
          "y": {
            "type": "category",
            "labels": [
              "U.S.",
              "China",
              "Japan",
              "Switzerland",
              "U.K.",
              "Germany",
              "Korea"
            ]
          }
        },
        "series": [
          {
            "name": "Number of Deals",
            "unit": "Deals",
            "values": [
              217,
              168,
              47,
              31,
              30,
              26,
              26
            ]
          }
        ],
        "figure_id": "6f06630a5b561602",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "bar",
        "title": "Main patent expiries ($bn)",
        "page": 1,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2024",
              "2025e",
              "2026e",
              "2027e",
              "2028e",
              "2029e",
              "2030E"
            ]
          },
          "y": {
            "unit": "$bn",
            "range": {
              "min": 0,
              "max": 35
            }
          }
        },
        "series": [
          {
            "name": "AZN",
            "unit": "$bn",
            "values": [
              0.2,
              0.5,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "BAYN",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "GSK",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "IPN",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "MRK",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "NOVN",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "NOVOB",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "ROG",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "SAN",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          },
          {
            "name": "UCB",
            "unit": "$bn",
            "values": [
              0.1,
              0.2,
              0.1,
              0.1,
              0.1,
              0.1,
              0.1
            ]
          }
        ],
        "figure_id": "1e647c48a1cd7db8",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "bar",
        "title": "# Deals Grouped by Phase and TA 2025 YTD",
        "page": 4,
        "axes": {
          "x": {
            "type": "value",
            "unit": "Deals",
            "range": {
              "min": 0,
              "max": 200
            }
          },
          "y": {
            "type": "category",
            "labels": [
              "Oncology",
              "Eye disease",
              "Auto-immune",
              "CVM",
              "Hematology",
              "Neurology",
              "Infection",
              "Dermatology",
              "Gastroenterology",
              "Urology",
              "Respiration",
              "Ophthalmology",
              "Renal disease",
              "Psychiatry",
              "Others",
              "Anesthesiology",
              "Diagnostic reagent",
              "Otolaryngology",
              "Overdose"
            ]
          }
        },
        "series": [
          {
            "name": "Pre-clinical + IND",
            "unit": "Deals",
            "values": [
              30,
              25,
              20,
              15,
              15,
              10,
              10,
              10,
              8,
              8,
              7,
              7,
              5,
              5,
              3,
              3,
              2,
              2,
              1
            ]
          },
          {
            "name": "P1 & 1/2",
            "unit": "Deals",
            "values": [
              35,
              30,
              25,
              20,
              20,
              15,
              15,
              15,
              10,
              10,
              8,
              8,
              7,
              7,
              5,
              5,
              3,
              3,
              1
            ]
          },
          {
            "name": "P2 & 2/3",
            "unit": "Deals",
            "values": [
              15,
              10,
              10,
              8,
              8,
              7,
              7,
              7,
              5,
              5,
              4,
              4,
              3,
              3,
              2,
              2,
              1,
              1,
              0
            ]
          },
          {
            "name": "P3 & NDA",
            "unit": "Deals",
            "values": [
              80,
              70,
              60,
              50,
              50,
              45,
              45,
              45,
              35,
              35,
              30,
              30,
              25,
              25,
              15,
              15,
              10,
              10,
              5
            ]
          },
          {
            "name": "Approved",
            "unit": "Deals",
            "values": [
              50,
              45,
              40,
              35,
              35,
              30,
              30,
              30,
              25,
              25,
              20,
              20,
              15,
              15,
              10,
              10,
              5,
              5,
              2
            ]
          }
        ],
        "figure_id": "9be8621bc9be23d9",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "bar",
        "title": "Total Target Countries for M&A 2025 YTD (Sum of TDV, US$ Bn)",
        "page": 3,
        "axes": {
          "x": {
            "type": "value",
            "labels": [
              "0",
              "20",
              "40",
              "60",
              "80"
            ]
          },
          "y": {
            "type": "category",
            "labels": [
              "U.S.",
              "Europe",
              "China",
              "Others"
            ]
          }
        },
        "series": [
          {
            "name": "Sum of TDV",
            "unit": "US$ Bn",
            "values": [
              {
                "category": "U.S.",
                "value": 49.7
              },
              {
                "category": "Europe",
                "value": 14.5
              },
              {
                "category": "China",
                "value": 1.2
              },
              {
                "category": "Others",
                "value": 0.4
              }
            ]
          }
        ],
        "figure_id": "691b359fd3c6db53",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "bar",
        "title": "China innovative drugs out-licensed overseas since 2022 (≥US$500 Mn) by modality",
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2022",
              "2023",
              "2024",
              "2025YTD*"
            ]
          },
          "y": {
            "unit": "count",
            "range": {
              "min": 0,
              "max": 44
            }
          }
        },
        "series": [
          {
            "name": "ADCs",
            "unit": "count",
            "values": [
              8,
              11,
              10,
              7
            ]
          },
          {
            "name": "Small molecules",
            "unit": "count",
            "values": [
              1,
              6,
              10,
              6
            ]
          },
          {
            "name": "mAb",
            "unit": "count",
            "values": [
              2,
              3,
              5,
              3
            ]
          },
          {
            "name": "BsAb",
            "unit": "count",
            "values": [
              1,
              3,
              6,
              3
            ]
          },
          {
            "name": "RNAi",
            "unit": "count",
            "values": [
              0,
              0,
              4,
              4
            ]
          },
          {
            "name": "Platform",
            "unit": "count",
            "values": [
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "Others",
            "unit": "count",
            "values": [
              1,
              1,
              6,
              6
            ]
          }
        ],
        "figure_id": "121d0288e186aea0",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "bar",
        "title": "No. of US Biotech IPOs",
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2021",
              "2022",
              "2023",
              "2024",
              "2025YTD"
            ]
          },
          "y": {
            "unit": "count",
            "range": {
              "min": 0,
              "max": 80
            }
          }
        },
        "series": [
          {
            "name": "No. of US Biotech IPOs",
            "unit": "count",
            "values": [
              75,
              17,
              12,
              21,
              3
            ]
          }
        ],
        "figure_id": "e1184339a39e98a9",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "bar",
        "title": "Top Out-license Countries in 2022 by # Deals",
        "page": 3,
        "axes": {
          "x": {
            "type": "value",
            "labels": [
              "0",
              "50",
              "100",
              "150",
              "200",
              "250",
              "300"
            ]
          },
          "y": {
            "type": "category",
            "labels": [
              "U.S.",
              "China",
              "U.K.",
              "Switzerland",
              "Japan",
              "Korea",
              "Germany"
            ]
          }
        },
        "series": [
          {
            "name": "Deals",
            "unit": "#",
            "values": [
              290,
              141,
              41,
              41,
              41,
              30,
              29
            ]
          }
        ],
        "figure_id": "7c45d8a21550cbd6",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "bar",
        "title": "Top In-license Countries in 2025 YTD by # Deals",
        "page": 3,
        "axes": {
          "x": {
            "type": "value",
            "unit": "Deals",
            "range": {
              "min": 0,
              "max": 300
            }
          },
          "y": {
            "type": "category",
            "labels": [
              "U.S.",
              "China",
              "Korea",
              "Japan",
              "U.K.",
              "Germany",
              "France"
            ]
          }
        },
        "series": [
          {
            "name": "Deals",
            "unit": "Deals",
            "values": [
              149,
              89,
              39,
              37,
              21,
              19,
              14
            ]
          }
        ],
        "figure_id": "b33e618c8d8c313a",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "bar",
        "title": "Top Acquirer Countries for M&A 2025 YTD (Sum of TDV, US$ Bn)",
        "page": 3,
        "axes": {
          "x": {
            "type": "value",
            "unit": "US$ Bn",
            "range": {
              "min": 0,
              "max": 80
            }
          },
          "y": {
            "type": "category",
            "labels": [
              "U.S.",
              "Europe",
              "Japan",
              "China",
              "Others"
            ]
          }
        },
        "series": [
          {
            "name": "Sum of TDV",
            "unit": "US$ Bn",
            "values": [
              37.2,
              25.8,
              1.2,
              1.2,
              0.4
            ]
          }
        ],
        "figure_id": "03748a3a793fce4f",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "cf4ca0f7cc65e2b4",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "bar",
        "title": "Top Out-license Countries 2025 YTD by # Deal (Top 20 MNC shopping)",
        "page": 4,
        "axes": {
          "x": {
            "type": "value",
            "labels": [
              "0",
              "20",
              "40",
              "60",
              "80",
              "100"
            ]
          },
          "y": {
            "unit": "Country",
            "range": {
              "min": null,
              "max": null
            }
          }
        },
        "series": [
          {
            "name": "Number of Deals",
            "unit": "deals",
            "values": [
              {
                "country": "U.S.",
                "value": 47
              },
              {
                "country": "China",
                "value": 18
              },
              {
                "country": "U.K.",
                "value": 5
              },
              {
                "country": "Denmark",
                "value": 3
              },
              {
                "country": "Germany",
                "value": 3
              },
              {
                "country": "Switzerland",
                "value": 3
              },
              {
                "country": "Korea",
                "value": 3
              }
            ]
          }
        ],
        "figure_id": "2c7c78a1513671a1",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": "Average upfront payment per deal",
        "page": 7,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2020",
              "2021",
              "2022",
              "2023",
              "2024",
              "2025YTD"
            ]
          },
          "y": {
            "unit": "US$ Mn",
            "range": {
              "min": 0,
              "max": 60
            }
          }
        },
        "series": [
          {
            "name": "CN out-licensing",
            "unit": "US$ Mn",
            "values": [
              10,
              42,
              26,
              42,
              44,
              52
            ]
          },
          {
            "name": "US/EU/JP/KR deals",
            "unit": "US$ Mn",
            "values": [
              34,
              22,
              32,
              31,
              24,
              30
            ]
          }
        ],
        "figure_id": "ec8ee1e9785c996a",
        "provenance": {
          "page": 7
        }
      },
      {
        "type": "bar",
        "title": "Top In-license Countries 2025 YTD by # Deal (Top 20 MNC shopping)",
        "page": 4,
        "axes": {
          "x": {
            "type": "value",
            "labels": [
              "0",
              "20",
              "40",
              "60",
              "80",
              "100"
            ]
          },
          "y": {
            "unit": "Country",
            "range": {
              "min": 0,
              "max": 7
            }
          }
        },
        "series": [
          {
            "name": "Number of Deals",
            "unit": "deals",
            "values": [
              {
                "country": "U.S.",
                "value": 38
              },
              {
                "country": "Germany",
                "value": 13
              },
              {
                "country": "Switzerland",
                "value": 9
              },
              {
                "country": "Denmark",
                "value": 9
              },
              {
                "country": "U.K.",
                "value": 8
              },
              {
                "country": "France",
                "value": 8
              },
              {
                "country": "Japan",
                "value": 3
              }
            ]
          }
        ],
        "figure_id": "644b66aff56e25a4",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "combo",
        "title": "Global Large Pharma M&A Total Deal Value (US$ Bn)",
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2018",
              "2019",
              "2020",
              "2021",
              "2022",
              "2023",
              "2024",
              "2025 YTD"
            ]
          },
          "y": {
            "unit": "US$ Bn",
            "range": {
              "min": 0,
              "max": 350
            }
          }
        },
        "series": [
          {
            "name": "Volume (LHS)",
            "unit": "US$ Bn",
            "values": [
              181,
              299,
              124,
              63,
              125,
              142,
              59,
              58
            ]
          },
          {
            "name": "Deal Count (LHS)",
            "unit": null,
            "values": [
              170,
              155,
              175,
              185,
              145,
              150,
              170,
              160
            ]
          },
          {
            "name": "Average Premium (RHS)",
            "unit": "%",
            "values": [
              70,
              120,
              65,
              85,
              95,
              75,
              100,
              55
            ]
          }
        ],
        "figure_id": "994c38a931741854",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "bar",
        "title": "Top In-license Countries in 2022 by # Deal (Top 20 MNC shopping)",
        "page": 4,
        "axes": {
          "x": {
            "type": "value",
            "labels": [
              "0",
              "20",
              "40",
              "60",
              "80",
              "100"
            ]
          },
          "y": {
            "unit": "country",
            "range": {
              "min": 0,
              "max": 71
            }
          }
        },
        "series": [
          {
            "name": "Number of Deals",
            "unit": "# Deal",
            "values": [
              {
                "country": "U.S.",
                "value": 71
              },
              {
                "country": "Switzerland",
                "value": 14
              },
              {
                "country": "Japan",
                "value": 13
              },
              {
                "country": "U.K.",
                "value": 12
              },
              {
                "country": "France",
                "value": 11
              },
              {
                "country": "Germany",
                "value": 10
              },
              {
                "country": "Denmark",
                "value": 5
              }
            ]
          }
        ],
        "figure_id": "752e5afe3e001ad7",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "bar",
        "title": "No. of IPOs of China Pharma and Biotech Companies on HKEX",
        "page": 6,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "2021",
              "2022",
              "2023",
              "2024",
              "2025YTD"
            ]
          },
          "y": {
            "unit": "Number of IPOs",
            "range": {
              "min": 0,
              "max": 10
            }
          }
        },
        "series": [
          {
            "name": "Biotech",
            "unit": "Number of IPOs",
            "values": [
              9,
              5,
              6,
              5,
              6
            ]
          },
          {
            "name": "Pharma",
            "unit": "Number of IPOs",
            "values": [
              5,
              1,
              3,
              1,
              1
            ]
          }
        ],
        "figure_id": "4daab837af8e73b4",
        "provenance": {
          "page": 6
        }
      },
      {
        "type": "bar",
        "title": "License + Large Pharma M&A Total Deal Value Jan 24 - July 25 (US$ Mn)",
        "page": 2,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jan-24",
              "Feb-24",
              "Mar-24",
              "Apr-24",
              "May-24",
              "Jun-24",
              "Jul-24",
              "Aug-24",
              "Sep-24",
              "Oct-24",
              "Nov-24",
              "Dec-24",
              "Jan-25",
              "Feb-25",
              "Mar-25",
              "Apr-25",
              "May-25",
              "Jun-25",
              "Jul-25"
            ]
          },
          "y": {
            "unit": "US$ Mn",
            "range": {
              "min": 0,
              "max": 60
            }
          }
        },
        "series": [
          {
            "name": "License total (US$ Bn)",
            "unit": "US$ Bn",
            "values": [
              17,
              5,
              6,
              10,
              18,
              10,
              9,
              9,
              7,
              18,
              27,
              19,
              30,
              7,
              27,
              5,
              15,
              38,
              21
            ]
          },
          {
            "name": "M&A total (US$ Bn)",
            "unit": "US$ Bn",
            "values": [
              5,
              15,
              6,
              13,
              5,
              2,
              4,
              2,
              2,
              3,
              2,
              3,
              19,
              7,
              2,
              1,
              3,
              14,
              12
            ]
          }
        ],
        "figure_id": "39b5e74be284c4c9",
        "provenance": {
          "page": 2
        }
      },
      {
        "type": "bar",
        "title": "Top Out-license Countries in 2022 by # Deal (Top 20 MNC shopping)",
        "page": 4,
        "axes": {
          "x": {
            "type": "value",
            "labels": null
          },
          "y": {
            "unit": "count",
            "range": null
          }
        },
        "series": [
          {
            "name": "Number of Deals",
            "unit": "count",
            "values": [
              {
                "country": "U.S.",
                "value": 84
              },
              {
                "country": "China",
                "value": 15
              },
              {
                "country": "U.K.",
                "value": 11
              },
              {
                "country": "Japan",
                "value": 9
              },
              {
                "country": "Germany",
                "value": 8
              },
              {
                "country": "Canada",
                "value": 6
              },
              {
                "country": "Switzerland",
                "value": 4
              }
            ]
          }
        ],
        "figure_id": "b423395272a72ada",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "pie",
        "title": "Global Innovative Drugs License Activity by Modality",
        "page": 4,
        "axes": {
          "x": null,
          "y": null
        },
        "series": [
          {
            "name": "Small molecule",
            "unit": "count",
            "values": [
              154
            ]
          },
          {
            "name": "mAb",
            "unit": "count",
            "values": [
              44
            ]
          },
          {
            "name": "Polypeptide",
            "unit": "count",
            "values": [
              26
            ]
          },
          {
            "name": "ADC",
            "unit": "count",
            "values": [
              24
            ]
          },
          {
            "name": "BsAb",
            "unit": "count",
            "values": [
              22
            ]
          },
          {
            "name": "Combo",
            "unit": "count",
            "values": [
              18
            ]
          },
          {
            "name": "Vaccine",
            "unit": "count",
            "values": [
              17
            ]
          },
          {
            "name": "Cell therapy",
            "unit": "count",
            "values": [
              17
            ]
          },
          {
            "name": "Nucleid",
            "unit": "count",
            "values": [
              15
            ]
          },
          {
            "name": "Fusion protein",
            "unit": "count",
            "values": [
              12
            ]
          },
          {
            "name": "Gene therapy",
            "unit": "count",
            "values": [
              11
            ]
          },
          {
            "name": "TCM",
            "unit": "count",
            "values": [
              7
            ]
          },
          {
            "name": "TriAb",
            "unit": "count",
            "values": [
              2
            ]
          },
          {
            "name": "Others",
            "unit": "count",
            "values": [
              51
            ]
          }
        ],
        "figure_id": "ea07056866065b5f",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "bar",
        "title": "Top Out-license Countries in 2025 YTD by # Deals",
        "page": 3,
        "axes": {
          "x": {
            "type": "value",
            "unit": "# Deals",
            "range": {
              "min": 0,
              "max": 300
            }
          },
          "y": {
            "type": "category",
            "labels": [
              "U.S.",
              "China",
              "Korea",
              "U.K.",
              "Japan",
              "Germany",
              "Switzerland"
            ]
          }
        },
        "series": [
          {
            "name": "# Deals",
            "unit": "Deals",
            "values": [
              180,
              156,
              34,
              25,
              23,
              19,
              16
            ]
          }
        ],
        "figure_id": "df035d0645c81fa1",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "bar",
        "title": "Top Target Countries for M&A in 2022 (Sum of TDV, US$ Bn)",
        "page": 3,
        "axes": {
          "x": {
            "type": "value",
            "unit": "US$ Bn",
            "range": {
              "min": 0,
              "max": 60
            }
          },
          "y": {
            "type": "category",
            "labels": [
              "U.S.",
              "Europe",
              "South Korea",
              "China",
              "Others"
            ]
          }
        },
        "series": [
          {
            "name": "TDV",
            "unit": "US$ Bn",
            "values": [
              52.7,
              32.5,
              2.3,
              1.4,
              1.9
            ]
          }
        ],
        "figure_id": "53f013b77eeb4bd4",
        "provenance": {
          "page": 3
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "1c1cc4f8957e6654",
        "value": 0.25,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t- LOE is Humira. Once the global best- selling drug with over \\$20 Bn sales in 2021- 2022, lost c. 25% of its business in 2023, the first year post LOE, and further shrank to less than a half (\\$9 Bn",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "384bfa74bc57f9de",
        "value": 30000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ed at hundreds of billions (Exhibit 1, Exhibit 2). This includes top- selling drugs like Keytruda (\\$30 Bn), Opdivo (\\$ Ozempic (\\$17 Bn), Eyelea (\\$5 Bn), Entresto (\\$4 Bn), to name a few. A famous e",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2989a07b56a06576",
        "value": 17000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "hibit 1, Exhibit 2). This includes top- selling drugs like Keytruda (\\$30 Bn), Opdivo (\\$ Ozempic (\\$17 Bn), Eyelea (\\$5 Bn), Entresto (\\$4 Bn), to name a few. A famous example of sales loss post- LOE",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "bf18e2d8504697b6",
        "value": 5000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "). This includes top- selling drugs like Keytruda (\\$30 Bn), Opdivo (\\$ Ozempic (\\$17 Bn), Eyelea (\\$5 Bn), Entresto (\\$4 Bn), to name a few. A famous example of sales loss post- LOE is Humira. Once t",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "25baa0ea973a138a",
        "value": 4000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "p- selling drugs like Keytruda (\\$30 Bn), Opdivo (\\$ Ozempic (\\$17 Bn), Eyelea (\\$5 Bn), Entresto (\\$4 Bn), to name a few. A famous example of sales loss post- LOE is Humira. Once the global best- sel",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "efa3d1050d7d55b8",
        "value": 20000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": ". A famous example of sales loss post- LOE is Humira. Once the global best- selling drug with over \\$20 Bn sales in 2021- 2022, lost c. 25% of its business in 2023, the first year post LOE, and furthe",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "02a7cf188d49f29d",
        "value": 9000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "t c. 25% of its business in 2023, the first year post LOE, and further shrank to less than a half (\\$9 Bn) in 2024. With the looming waves of LOE, Big Pharma has to stock up their pipelines faster tha",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f097c37b39d28a71",
        "value": 1.26,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "f Allergan at US\\) 63Bn and BMS's purchase of Celgene at US \\(74Bn, with an average deal premium of 126%. The following years were quite stable in deal numbers but saw a significant decrease in total ",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "5e94d737da00284d",
        "value": 0.6,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "g behind previous years. In general, large pharma M&A activities carry an average deal premium of \\~60%- 90%, representing a favorable position in the capital market (Exhibit 3). ![Figure 1-1](images/",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "2e729054ab10977d",
        "value": 0.9,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ind previous years. In general, large pharma M&A activities carry an average deal premium of \\~60%- 90%, representing a favorable position in the capital market (Exhibit 3). ![Figure 1-1](images/1_1.j",
        "provenance": {
          "page": 1
        }
      },
      {
        "num_id": "d85c782e4ec8f0d1",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "n, 2025 YTD vs. 2022). Most buyers of U.S. targets are domestic, accounting for 37 out of 53 deals (70%, percentage unchanged from 2022). There was a decline of interest in Europe (US\\$14.5 Bn vs. 32.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "20c7369d1eeb1c22",
        "value": 49700000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "On the deal target side, U.S. is still the most favorable target country for M&A activities (US\\$49.7 Bn vs. 52.7 Bn, 2025 YTD vs. 2022). Most buyers of U.S. targets are domestic, accounting for 37 ou",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "4dbbe8ba64cc8c00",
        "value": 14500000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ut of 53 deals (70%, percentage unchanged from 2022). There was a decline of interest in Europe (US\\$14.5 Bn vs. 32.5 Bn, 2025 YTD vs. 2022), mainly contributed by a decrease in Amgen's investment (US",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "8de485c579f7ed67",
        "value": 27800000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "14.5 Bn vs. 32.5 Bn, 2025 YTD vs. 2022), mainly contributed by a decrease in Amgen's investment (US\\$27.8 Bn vs. none, 2025 YTD vs. 2022), and offset by Merck & Co.'s acquisition of Verona Pharma at T",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "2834c94a0de572aa",
        "value": 10000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "vs. none, 2025 YTD vs. 2022), and offset by Merck & Co.'s acquisition of Verona Pharma at TDV of US\\$10 Bn earlier this year (Exhibit 8, Exhibit 9). ![Figure 2-0](images/2_0.jpg) <center>EXHIBIT 6: U.",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "b958bc20620aaac2",
        "value": 3000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "in 2017, total value of out- licensing activities from China to global top 20 MNCs was a mere of US\\$ 3 Bn, but has soared to US\\$ 19 Bn in 2022 and US\\$ 39 Bn in 2025 YTD. Though total value has been",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "0ef33e92149c2126",
        "value": 19000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "licensing activities from China to global top 20 MNCs was a mere of US\\$ 3 Bn, but has soared to US\\$ 19 Bn in 2022 and US\\$ 39 Bn in 2025 YTD. Though total value has been increasing, we do not see mu",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "962fcc0e06e89e97",
        "value": 39000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "om China to global top 20 MNCs was a mere of US\\$ 3 Bn, but has soared to US\\$ 19 Bn in 2022 and US\\$ 39 Bn in 2025 YTD. Though total value has been increasing, we do not see much difference in the nu",
        "provenance": {
          "page": 2
        }
      },
      {
        "num_id": "ac52ec7973868613",
        "value": 0.37,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "owed by some other heated TAs, including autoimmune and CVM. In terms of modality, small molecules (37%) and monoclonal antibodies (11%) remain the most sought- after assets classes, followed by ADCs ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a6803d835b033b70",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ncluding autoimmune and CVM. In terms of modality, small molecules (37%) and monoclonal antibodies (11%) remain the most sought- after assets classes, followed by ADCs and BsAbs. (Exhibit 18, Exhibit ",
        "provenance": {
          "page": 3
        }
      },
      {
        "num_id": "a8fd90cef7f414bb",
        "value": 0.51,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d surpassed the rest of world (US, EU, Japan, Russia, Korea, and India) for the first time in 2025 (51% of global), with a focus on oncology. The rising global relevance is not just in the quantity of",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "1af1efecc489727b",
        "value": 0.8490000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ks in developed markets. During 2020 and 2021, Chinese deals posted relatively weaker durability at 84.9% and 78.9% (vs. 96.1% and 93.5% for US/EU/JP/KR). The trajectory shifted in 2022, with China re",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7a53245d83bcf64c",
        "value": 0.789,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "loped markets. During 2020 and 2021, Chinese deals posted relatively weaker durability at 84.9% and 78.9% (vs. 96.1% and 93.5% for US/EU/JP/KR). The trajectory shifted in 2022, with China rebounding t",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "493cbb34df8c8f8a",
        "value": 0.961,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ts. During 2020 and 2021, Chinese deals posted relatively weaker durability at 84.9% and 78.9% (vs. 96.1% and 93.5% for US/EU/JP/KR). The trajectory shifted in 2022, with China rebounding to 94.1% and",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "1bf39885af1e1f51",
        "value": 0.935,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2020 and 2021, Chinese deals posted relatively weaker durability at 84.9% and 78.9% (vs. 96.1% and 93.5% for US/EU/JP/KR). The trajectory shifted in 2022, with China rebounding to 94.1% and further ad",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "7c083d6ef110bc13",
        "value": 0.941,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".9% (vs. 96.1% and 93.5% for US/EU/JP/KR). The trajectory shifted in 2022, with China rebounding to 94.1% and further advancing to 97.6% in 2023, nearly matching the 99.2% level record globally. Such ",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "5a90b4345ba72800",
        "value": 0.976,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/EU/JP/KR). The trajectory shifted in 2022, with China rebounding to 94.1% and further advancing to 97.6% in 2023, nearly matching the 99.2% level record globally. Such trend could suggest the tangibl",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "831c0a1c212b1b29",
        "value": 0.992,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "in 2022, with China rebounding to 94.1% and further advancing to 97.6% in 2023, nearly matching the 99.2% level record globally. Such trend could suggest the tangible uplift in Chinese drug quality, w",
        "provenance": {
          "page": 4
        }
      },
      {
        "num_id": "6013c8d1aa94a03d",
        "value": 40.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "already surpassing the 2022 and 2024 level. Market cap raised also rebounded significantly, from HK\\$40- 70 Bn during 2022 to 2024 to HK\\$45 Bn in 1H25, alongside a major HK\\$256 Bn Hengrui listing (E",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "a0b596ffe5f1625d",
        "value": 45000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "level. Market cap raised also rebounded significantly, from HK\\$40- 70 Bn during 2022 to 2024 to HK\\$45 Bn in 1H25, alongside a major HK\\$256 Bn Hengrui listing (Exhibit 25- Exhibit 26). This recovery",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "8fad8b7814c872ee",
        "value": 256000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ed significantly, from HK\\$40- 70 Bn during 2022 to 2024 to HK\\$45 Bn in 1H25, alongside a major HK\\$256 Bn Hengrui listing (Exhibit 25- Exhibit 26). This recovery stands in sharp contrast to the U.S.",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "bcc353432297632d",
        "value": 62000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "h IPOs have collapsed from 75 listings in 2021 to only 3 in 1H25, with market cap shrinking from US\\$62 Bn to US \\$3 Bn (Exhibit 27- Exhibit 28). The robust IPO momentum seen in 1H25 highlights that I",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f1d05719253874de",
        "value": 3000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "llapsed from 75 listings in 2021 to only 3 in 1H25, with market cap shrinking from US\\$62 Bn to US \\$3 Bn (Exhibit 27- Exhibit 28). The robust IPO momentum seen in 1H25 highlights that IPOs are re- em",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "93794472103100fb",
        "value": 62000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "ource: Bloomberg, Bernstein analysis </center> ## EXHIBIT 28: ...with market cap shrinking from US\\$62 Bn to US\\$3 Bn ![Figure 5-3](images/5_3.jpg) <center>Source: Bloomberg, Bernstein analysis </cent",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f23ba2543bbb9755",
        "value": 3000000000.0,
        "unit": "$",
        "metric_type": "currency",
        "context": "erg, Bernstein analysis </center> ## EXHIBIT 28: ...with market cap shrinking from US\\$62 Bn to US\\$3 Bn ![Figure 5-3](images/5_3.jpg) <center>Source: Bloomberg, Bernstein analysis </center> ![Figure",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ed81b0c7863090bd",
        "value": 2.046,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">2026E</td></tr><tr><td>9926.HK (Akeso)</td><td>O</td><td>HKD</td><td>156.00</td><td>143.00</td><td>204.6%</td><td>CNY</td><td>(0.60)</td><td>1.11</td><td>1.80</td><td>(236.1)</td><td>128.6</td><td>79",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "f99940bcf922cc13",
        "value": 0.33799999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>79.2</td></tr><tr><td>ONC (BeiGene)</td><td>M</td><td>USD</td><td>297.96</td><td>259.00</td><td>33.8%</td><td>USD</td><td>(6.12)</td><td>4.29</td><td>8.40</td><td>9.3</td><td>6.8</td><td>6.1</td><",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "219ee8f4e978a9c8",
        "value": 0.9059999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>6.1</td></tr><tr><td>1093.HK (CSPC)</td><td>M</td><td>HKD</td><td>10.11</td><td>10.70</td><td>90.6%</td><td>HKD</td><td>0.49</td><td>0.37</td><td>0.52</td><td>18.7</td><td>25.1</td><td>17.9</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "47dfbc816179f54a",
        "value": 1.0390000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "17.9</td></tr><tr><td>1801.HK (Innovent)</td><td>O</td><td>HKD</td><td>96.85</td><td>112.00</td><td>103.9%</td><td>HKD</td><td>(0.06)</td><td>0.82</td><td>1.11</td><td>41.3%</td><td>31.5%</td><td>38.0",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b5771e5338ddbf66",
        "value": 0.413,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>96.85</td><td>112.00</td><td>103.9%</td><td>HKD</td><td>(0.06)</td><td>0.82</td><td>1.11</td><td>41.3%</td><td>31.5%</td><td>38.0%</td></tr><tr><td>600276.CH (Hengrui)</td><td>O</td><td>CNY</td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "2ba48886b15abe8f",
        "value": 0.315,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>112.00</td><td>103.9%</td><td>HKD</td><td>(0.06)</td><td>0.82</td><td>1.11</td><td>41.3%</td><td>31.5%</td><td>38.0%</td></tr><tr><td>600276.CH (Hengrui)</td><td>O</td><td>CNY</td><td>66.23</td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "f4291155520bb80f",
        "value": 0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>103.9%</td><td>HKD</td><td>(0.06)</td><td>0.82</td><td>1.11</td><td>41.3%</td><td>31.5%</td><td>38.0%</td></tr><tr><td>600276.CH (Hengrui)</td><td>O</td><td>CNY</td><td>66.23</td><td>74.00</td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "b357c30d00fd0a1e",
        "value": 0.307,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8.0%</td></tr><tr><td>600276.CH (Hengrui)</td><td>O</td><td>CNY</td><td>66.23</td><td>74.00</td><td>30.7%</td><td>CNY</td><td>1.00</td><td>1.43</td><td>1.47</td><td>66.2</td><td>46.3</td><td>45.1</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "45fbf62890e28dd9",
        "value": 1.331,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">45.1</td></tr><tr><td>1177.HK (Sino BioPh)</td><td>M</td><td>HKD</td><td>8.11</td><td>7.90</td><td>133.1%</td><td>CNY</td><td>0.19</td><td>0.20</td><td>0.22</td><td>38.8</td><td>37.4</td><td>33.9</td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "2c07a134e90260da",
        "value": 0.561,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d>33.9</td></tr><tr><td>9688.HK (Zai Lab)</td><td>M</td><td>HKD</td><td>25.60</td><td>28.00</td><td>56.1%</td><td>USD</td><td>(0.26)</td><td>(0.13)</td><td>(0.04)</td><td>(12.6)</td><td>(24.5)</td><td",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "8f5035b1843986b1",
        "value": 0.254,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "32.0</td><td>24.3</td></tr><tr><td>GILD</td><td>O</td><td>USD</td><td>112.56</td><td>135.00</td><td>25.4%</td><td>USD</td><td>4.61</td><td>8.16</td><td>8.87</td><td>24.4</td><td>13.8</td><td>12.7</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "ae882dcc9401e4bf",
        "value": 0.11,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1.1</td><td>9.6</td></tr><tr><td>UCB.BB</td><td>M</td><td>EUR</td><td>200.40</td><td>197.00</td><td>11.0%</td><td>EUR</td><td>4.86</td><td>7.19</td><td>9.53</td><td>41.2</td><td>27.9</td><td>21.0</td>",
        "provenance": {
          "page": 7
        }
      },
      {
        "num_id": "972733c933b0701e",
        "value": 0.5127,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Percent</td><td>Count*</td><td>Percent*</td></tr><tr><td>Outperform</td><td>BUY</td><td>585</td><td>51.27%</td><td>110</td><td>18.80%</td></tr><tr><td>Market-Perform (Bernstein Brand)</td><td rowspan=",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ade510cb75dbdcb7",
        "value": 0.188,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Percent*</td></tr><tr><td>Outperform</td><td>BUY</td><td>585</td><td>51.27%</td><td>110</td><td>18.80%</td></tr><tr><td>Market-Perform (Bernstein Brand)</td><td rowspan=\"2\">HOLD</td><td rowspan=\"2",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "64f0de0b16513448",
        "value": 0.3567,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rket-Perform (Bernstein Brand)</td><td rowspan=\"2\">HOLD</td><td rowspan=\"2\">407</td><td rowspan=\"2\">35.67%</td><td rowspan=\"2\">76</td><td rowspan=\"2\">18.67%</td></tr><tr><td>Neutral (Autonomous Brand)",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "4930f2f022848135",
        "value": 0.1867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">HOLD</td><td rowspan=\"2\">407</td><td rowspan=\"2\">35.67%</td><td rowspan=\"2\">76</td><td rowspan=\"2\">18.67%</td></tr><tr><td>Neutral (Autonomous Brand)</td></tr><tr><td>Underperform</td><td>SELL</td><t",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "f51d228ae8ed7a39",
        "value": 0.1306,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Neutral (Autonomous Brand)</td></tr><tr><td>Underperform</td><td>SELL</td><td>149</td><td>13.06%</td><td>20</td><td>13.42%</td></tr></table> \\* These figures represent the number and percent",
        "provenance": {
          "page": 9
        }
      },
      {
        "num_id": "ef6973d72f848fcc",
        "value": 0.13419999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ous Brand)</td></tr><tr><td>Underperform</td><td>SELL</td><td>149</td><td>13.06%</td><td>20</td><td>13.42%</td></tr></table> \\* These figures represent the number and percentage of companies in each c",
        "provenance": {
          "page": 9
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 29,
      "tables_count": 0,
      "numerical_data_count": 53,
      "passages_count": 173,
      "entities_count": 20
    }
  }
}